oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort
Med Sect, Ctr Digest Dis, Herlev Univ Hosp, Copenhagen, Denmark.
Med Sect, Ctr Digest Dis, Herlev Univ Hosp, Copenhagen, Denmark.
Univ Hosp Ctr Zagreb, Div Gastroenterol & Hepatol, Univ Zagreb School of Medicine, Zagreb, Croatia.
Univ Hosp Ctr Zagreb, Div Gastroenterol & Hepatol, Univ Zagreb School of Medicine, Zagreb, Croatia.
Show others and affiliations
2014 (English)In: Inflammatory Bowel Diseases, ISSN 1078-0998, E-ISSN 1536-4844, Vol. 20, no 1, p. 36-46Article in journal (Refereed) Published
Abstract [en]

Background:The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort.

Methods:Patients were followed-up every third month during the first 12 (3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu).

Results:In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe.

Discussion:In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2014. Vol. 20, no 1, p. 36-46
Keywords [en]
epidemiology, outcomes research, Crohn's disease, ulcerative colitis
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-33695DOI: 10.1097/01.MIB.0000436277.13917.c4ISI: 000329353600007PubMedID: 24252978Scopus ID: 2-s2.0-84893671655OAI: oai:DiVA.org:oru-33695DiVA, id: diva2:695921
Funder
Swedish Research Council
Note

Funding Agencies:

Danish Colitis Crohn Patients Organization     

Vibeke Binder and Povl Riis' Foundation     

Scientific Council at the Herlev Hospital     

Sigrid Rigmor Moran Foundation     

Aage and Johanne Louis-Hansens Foundation     

Munkholm Foundation

C.C. Klestrup and Henriette Klestrup Foundation

Knud and Dagny Gad Andresens Foundation

Else and Mogens Wedell-Wedellsborgs Foundation

Direktor Jacob Madsen and Olga Madsens Foundation     

ScanVet     

Torben og Alice Frimodt Foundation     

Laegernes forsikringsforening     

Bengt Ihres Foundation     

Nanna Svartz Foundation     

Orebro University Hospital Research Foundation     

Orebro County Research Foundation     

Swedish Foundation for Gastrointestinal Research     

Swedish Society of Medicine     

Research Council of South-East Sweden     

County Council of Ostergotland     

Swedish Organization for the Study of Inflammatory Bowel Disease     

Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital     

European Crohn's and Colitis Organization

Available from: 2014-02-12 Created: 2014-02-12 Last updated: 2018-06-04Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Zhulina, YaroslavaHalfvarson, Jonas

Search in DiVA

By author/editor
Zhulina, YaroslavaHalfvarson, Jonas
By organisation
School of Health and Medical Sciences, Örebro University, SwedenÖrebro University HospitalSchool of Medicine, Örebro University, Sweden
In the same journal
Inflammatory Bowel Diseases
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 388 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf